» Articles » PMID: 30642351

Context-dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer Proliferation and Circulating Tumor Cells

Overview
Specialty Oncology
Date 2019 Jan 16
PMID 30642351
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Many human breast cancers overexpress the E3 ubiquitin ligase MDM2 and its homolog MDMX. Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα) breast cancer and triple-negative breast cancer (TNBC). There are p53-independent influences of MDM2 and MDMX, and 80% of TNBC express mutant p53 (mtp53). MDM2 drives TNBC circulating tumor cells (CTCs) in mice, but the context-dependent influences of MDM2 and MDMX on different subtypes of breast cancers expressing mtp53 have not been determined.

Methods: To assess the context-dependent roles, we carried out MDM2 and MDMX knockdown in orthotopic tumors of TNBC MDA-MB-231 cells expressing mtp53 R280K and MDM2 knockdown in ERα T47D cells expressing mtp53 L194F. The corresponding cell proliferation was scored in vitro by growth curves and in vivo by orthotopic tumor volumes. Cell migration was assessed in vitro by wound-healing assays and cell intravasation in vivo by sorting GFP-positive CTCs by flow cytometry. The metastasis gene targets were determined by an RT-PCR array card screen and verified by qRT-PCR and Western blot analysis.

Results: Knocking down MDMX or MDM2 in MDA-MB-231 cells reduced cell migration and CTC detection, but only MDMX knockdown reduced tumor volumes at early time points. This is the first report of MDMX overexpression in TNBC enhancing the CTC phenotype with correlated upregulation of CXCR4. Experiments were carried out to compare MDM2-knockdown outcomes in nonmetastatic ERα T47D cells. The knockdown of MDM2 in ERα T47D orthotopic tumors decreased primary tumor volumes, supporting our previous finding that estrogen-activated MDM2 increases cell proliferation.

Conclusions: This is the first report showing that the expression of MDM2 in ERα breast cancer and TNBC can result in different tumor-promoting outcomes. Both MDMX and MDM2 overexpression in TNBC MDA-MB-231 cells enhanced the CTC phenotype. These data indicate that both MDM2 and MDMX can promote TNBC metastasis and that it is important to consider the context-dependent roles of MDM2 family members in different subtypes of breast cancer.

Citing Articles

Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis.

Lee R, Ellison V, Forbes D, Gao C, Katanov D, Kern A Cancers (Basel). 2025; 16(24.

PMID: 39766093 PMC: 11674518. DOI: 10.3390/cancers16244194.


Integration of RNA Editing with Multiomics Data Improves Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients.

Bernal Y, Blanco A, Orostica K, Delgado I, Armisen R Res Sq. 2025; .

PMID: 39764127 PMC: 11702790. DOI: 10.21203/rs.3.rs-5604105/v1.


Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target.

Duan H, Ren J, Wei S, Yang Z, Li C, Wang Z Genome Med. 2024; 16(1):138.

PMID: 39593114 PMC: 11590298. DOI: 10.1186/s13073-024-01410-8.


SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA.

Yu S, Si Y, Yu J, Jiang C, Cheng F, Xu M Cancer Sci. 2024; 115(12):3915-3927.

PMID: 39329452 PMC: 11611762. DOI: 10.1111/cas.16356.


Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53.

Muniz de Queiroz R, Efe G, Guzman A, Hashimoto N, Kawashima Y, Tanaka T Nat Commun. 2024; 15(1):7132.

PMID: 39164253 PMC: 11336179. DOI: 10.1038/s41467-024-51488-2.


References
1.
Kenny P, Lee G, Myers C, Neve R, Semeiks J, Spellman P . The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2008; 1(1):84-96. PMC: 2391005. DOI: 10.1016/j.molonc.2007.02.004. View

2.
Pan Y, Chen J . MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol. 2003; 23(15):5113-21. PMC: 165735. DOI: 10.1128/MCB.23.15.5113-5121.2003. View

3.
Muller A, Homey B, Soto H, Ge N, CATRON D, Buchanan M . Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-6. DOI: 10.1038/35065016. View

4.
Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M . MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999; 447(1):5-9. DOI: 10.1016/s0014-5793(99)00254-9. View

5.
Fakharzadeh S, Trusko S, GEORGE D . Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991; 10(6):1565-9. PMC: 452821. DOI: 10.1002/j.1460-2075.1991.tb07676.x. View